Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c in Advanced Gastric Cancer
NCT04826107Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of DP303c in gastric cancer (GC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
DP303c
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04826107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826107.